martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· July 4, 2026

Real estate stocks eke out gains in June, post solid returns in four months of H1 2026

View original at seekingalpha.com
Real estate stocks eke out gains in June, post solid returns in four months of H1 2026 [Real estate entrepreneurs meeting to sell a house, discussing real estate deals, with house plans on the table, symbolizing real estate investment and negotiations.] Real estate stocks saw a strong close to the first half of 2026, p…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Expected book value erosion of $0.35-$0.45 per share from frictional costs, and potential further erosion of $0.58-$1.24 per share from asset sales, during the disposal period

    60% confidence
  • Oppenheimer analyst Jason Helfstein maintained a Buy rating on Compass (COMP) with a $15.00 price target after management met with the firm

    60% confidence
  • Citi upgraded American Healthcare REIT to Buy from Neutral, citing relative underperformance as an attractive entry point

    60% confidence
  • Citi cut Sabra Health to Neutral

    60% confidence
  • ARI had roughly $1.3B of cash and $462M of book value tied up in five real estate assets, and it will take 9 to 12 months to fully dispose of the five properties

    60% confidence
  • BTIG downgraded Apollo Commercial Real Estate Finance (ARI) to Neutral from Buy, citing that asset sales are expected to drag on book value

    60% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com